Kaplan‒Meier analysis showed that the higher expression of SETDB1 predicted poor progression-free survival (PFS) and poor post-progression survival (PPS) in ovarian cancer patients (Fig. 1I and J). Here, SETDB1 is linked to ovarian carcinoma.